These include the upregulation of wild-type p53, the restoration of tumor-suppressive function in mutant p53, the induction of synthetic lethality through targeting collateral genome maintenance pathways, and strategies harnessing the immunogenicity of p53-pathway aberrations (Table 2). This evidence concerns the gene TP53 and neoplasm.